Toxicology studies on antineoplaston A10 injections in cancer patients

Antineoplaston A10 injections were administered to 18 patients diagnosed with 19 types of neoplastic disease. The patients' diagnoses included: adenocarcinoma of the rectum and colon, Stage IV (8 cases); adenocarcinoma of the pancreas (4 cases); adenocarcinoma of the breast, Stage IV (3 cases) and single cases of adenocarcinoma of the lungs, Stage III; adenocarcinoma of the stomach, Stage IV; chondrosarcoma of the nose and right maxillary sinus; and carcinoid. The treatment was administered from 52 to 640 days. The highest dosage taken was 2210.5 mg/kg/24 h. Most of the patients were taking from 206.9 to 387.1 mg/kg/24 h. The treatment was associated with minimal side-effects including febrile reactions, muscle and joint pain, muscle contraction in the throat, abdominal pain of short duration and single incidences of nausea, dizziness and headache. Desirable side-effects included increase of platelet count and white blood cell count. Objective response to the treatment was noticed in 8 patients including one patient diagnosed with intraductal carcinoma of the breast, Stage IV, 2 patients with adenocarcinoma of the sigmoid, Stage IV, 1 patient with adenocarcinoma of the rectum, Stage IV, 2 patients with adenocarcinoma of the pancreas, 1 patient with adenocarcinoma of the lung, Stage III, and 1 chondrosarcoma.